senicapoc has been researched along with Extravascular Hemolysis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ataga, KI; Brugnara, C; Staffa, SJ; Stocker, JW | 1 |
| Ataga, KI; Stocker, J | 1 |
| Ataga, KI; Ballas, SK; Bigelow, C; Galacteros, F; Hull, JH; James, LS; Kutlar, A; Reid, M; Smith, WR; Stocker, JW; Yasin, Z | 1 |
1 review(s) available for senicapoc and Extravascular Hemolysis
| Article | Year |
|---|---|
Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia.
Topics: Acetamides; Anemia, Sickle Cell; Animals; Animals, Genetically Modified; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Hemolysis; Humans; Mice; Trityl Compounds | 2009 |
1 trial(s) available for senicapoc and Extravascular Hemolysis
| Article | Year |
|---|---|
Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapo
Topics: Acetamides; Adolescent; Adult; Aged; Anemia, Sickle Cell; Antisickling Agents; Double-Blind Method; Drug Administration Schedule; Erythrocyte Aging; Female; Hematocrit; Hemolysis; Humans; Intermediate-Conductance Calcium-Activated Potassium Channels; Male; Middle Aged; Pain; Treatment Outcome; Trityl Compounds; Young Adult | 2011 |
1 other study(ies) available for senicapoc and Extravascular Hemolysis
| Article | Year |
|---|---|
Haemoglobin response to senicapoc in patients with sickle cell disease: a re-analysis of the Phase III trial.
Topics: Acetamides; Anemia, Sickle Cell; Benzaldehydes; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Hemoglobins; Hemolysis; Humans; Hydroxyurea; Intermediate-Conductance Calcium-Activated Potassium Channels; Pyrazines; Pyrazoles; Trityl Compounds | 2021 |